Early-stage multiple sclerosis: What are the treatment options?

Drugs

Volumn 64, Issue 18, 2004, Pages 2021-2029

  Sorensen, Per Soelberg ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; PLACEBO;

ANTIGEN RECOGNITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATION; DISEASE ACTIVITY; DISEASE COURSE; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OPTIC NERVE DISEASE; REMYELINIZATION; REVIEW;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TIME FACTORS;

EID: 4644370379     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464180-00002     Document Type: Review

References (54)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-76
5. Rieckmann P, Toyka KV. Escalating immunotherapy of multiple sclerosis: Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group (MSTCG). Eur Neurol 1999; 42: 121-7
6. McRae BL, Vanderlugt CL, Dal CM, et al. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995; 182: 75-85
7. Tuohy VK, Yu M, Yin L, et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 2004; 164: 93-100
8. Yu M, Johnson JM, Tuohy VK. Generation of autonomously pathogenic neo-autoreactive Th1 cells during the development of the determinant spreading cascade in murine autoimmune encephalomyelitis. J Neurosci Res 1996; 45 (4): 463-70
9. Tuohy VK, Yu M, Weinstock GB, et al. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 1997; 99: 1682-90
10. Yu M, Kinkel RP, Weinstock GB, et al. HLA-DP: a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis. Hum Immunol 1998; 59: 15-24
11. Nicoletti F, Di Marco R, Mangano K, et al. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology 2001; 57: 342-4
12. Balashov KE, Comabella M, Ohashi T, et al. Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS. Neurology 2000; 55: 192-8
13. Silber E, Semra YK, Gregson NA, et al. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002; 58: 1372-81
14. Eikelenboom MJ, Petzold A, Lazeron RH, et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003; 60: 219-3
15. Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720-5
16. Whitaker JN, Kachelhofer RD, Bradley EL, et al. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol 1995; 38: 625-2
17. Rodriguez M. Central nervous system demyelination and remyelination in multiple sclerosis and viral models of disease. J Neuroimmunol 1992; 40: 255-3
18. Prineas JW, Barnard RO, Revesz T, et al. Multiple sclerosis: pathology of recurrent lesions. Brain 1993; 116 (Pt 3): 681-3
19. Lucchinetti CF, Brack W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-74
20. Storch M, Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol 1997; 10: 186-92
21. Brack W, Schmied M, Suchanek G, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994; 35: 65-73
22. Raine CS, Wu E. Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 1993; 52: 199-204
23. Charcot JM. Histologie de la sclerose en plaque. Gazette Hopitalux (Paris) 1868; 41: 554-6
24. Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9
25. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85
26. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302
27. Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-12
28. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29: 548-55
29. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7
30. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31
31. Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002; 52: 47-53
32. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 1993; 116 (Pt 1): 135-46
33. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998; 121: 495-503
34. Sailer M, O'Riordan JI, Thompson AJ, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999; 52: 599-606
35. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44: 635-41
36. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-64
37. Traboulsee A, Dehmeshki J, Brex PA, et al. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology 2002; 59: 126-8
38. Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000; 54: 1689-91
39. Chard DT, Brex PA, Ciccarelli O, et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry 2003; 74: 1551-4
40. Kapeller P, Brex PA, Chard D, et al. Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2002; 8: 207-10
41. Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994; 36: 76-82
42. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121 (Pt 8): 1469-77
43. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis: the Optic Neuritis Study Group. N Engl J Med 1993; 329: 1764-9
44. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial: Optic Neuritis Study Group. Neurology 1997; 49: 1404-13
45. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis: CHAMPS Study Group. N Engl J Med 2000; 343: 898-904
46. Comi G, Filippi M. Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82
47. O'Connor P. The effects of intramuscular interferon beta-1a in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin Ther 2003; 25: 2865-74
48. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51: 481-90
49. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology 1999; 53: 679-86
50. Andersen O, Elovaara I, Färkkilä M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis: the Nordic SPMS Study Group. J Neurol Neurosurg Psychiatry 2004; 75 (5): 706-10
51. Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol. In Press
52. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52
53. PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-36
54. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91